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Evaluation of prophylactic dosages of
Enoxaparin in non-surgical elderly patients
with renal impairment
Nibal Chamoun1* , Hady Ghanem2, Ahmad Hachem3†, Essa Hariri4†, Christelle Lteif1†, Hanine Mansour1†,
Hani Dimassi5, Richard Zalloum6 and Georges Ghanem6
Abstract
Background: Thromboprophylaxis dosing strategies using enoxaparin in elderly patients with renal disease are limited,
while dose adjustments or monitoring of anti-Xa levels are recommended. We sought to evaluate the efficacy and
safety of enoxaparin 20mg versus 30mg subcutaneously daily by comparing anti-Xa levels, thrombosis and bleeding.
Methods: We conducted a prospective, single-blinded, single-center randomized clinical trial including non-surgical
patients, 70 years of age or older, with renal disease requiring thromboprophylaxis. Patients were randomized to
receive either 20mg or 30mg of enoxaparin. The primary endpoint was peak anti-Xa levels on day 3. Secondary
endpoints included trough anti-Xa levels on day 3, achievement of within range prophylactic target peak anti-Xa levels
and the occurrence of hemorrhage, thrombosis, thrombocytopenia or hyperkalemia during hospitalization.
Results: Thirty-two patients were recruited and sixteen patients were randomized to each arm. Mean peak anti-Xa level
was significantly higher in 30mg arm (n = 13) compared to the 20mg arm (n= 11) 0.26 ± 0.11, 95%CI (0.18–0.34), versus
0.14 ± 0.09, 95CI (0.08–0.19) UI/ml, respectively; p= 0.004. Mean trough anti-Xa level was higher in 30mg arm (n = 10)
compared to the 20 mg arm (n = 16), 0.06 ± 0.03, 95CI (0.04–0.08) versus 0.03 ± 0.03, 95CI (0.01–0.05) UI/ml,
respectively; p = 0.044. Bleeding events reported in the 30 mg arm were one retroperitoneal bleed requiring
multiple transfusions, and in the 20 mg arm one hematuria. No thrombotic events were reported.
Conclusion: Peak anti-Xa levels provided by enoxaparin 20 mg were lower than the desired range for
thromboprophylaxis in comparison to enoxaparin 30 mg.
Trial registration: The trial was retrospectively registered on ClinicalTrials.gov identifier: NCT03158792.
Registered: May 18, 2017.
Keywords: Thromboprophylaxis, Enoxaparin, Renal impairment, Elderly, Anti-Xa, Venous thromboembolism
Introduction
Venous thromboembolism (VTE) is a common and pre-
ventable cause of hospital-related morbidity and mortal-
ity [1, 2]. While thromboprophylaxis dosing strategies
with low molecular weight heparins (LMWHs) are well
characterized for patients with normal renal function,
they are less established in renal impairment due to lim-
ited published literature, as these patients were excluded
from several landmark clinical trials [3–8]. Dosage
adjustment or monitoring of prophylactic doses of
LMWHs is recommended in select clinical scenarios, such
as renal impairment, by using the chromogenic assay
anti-Xa [9–12]. It is also important to note that patients
with renal impairment are at an increased risk of throm-
bosis and bleeding [13]. Moreover, elderly patients with a
concomitant picture of renal impairment are also under-
represented in clinical trials thus; thromboprophylaxis
presents a challenging situation for these patients [14].
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A gap in the literature exists regarding efficacy and safety
of different prophylactic doses of LMWHs in severe renal
impairment with creatinine clearance (CrCl) less than 30
mL/min [9, 15]. Prophylactic doses of tinzaparin and
dalteparin seem to be safe in renal impairment, whereas
drug accumulation has been demonstrated with enoxaparin
[3, 11, 16, 17]. Moreover, an inverse relationship has been
demonstrated via pharmacokinetic studies between CrCl
and LMWH anti-Xa levels, especially with enoxaparin, in
patients with severe renal impairment [3, 5, 9, 18]. Specific-
ally, studies in elderly patients with renal dysfunction re-
ceiving prophylactic enoxaparin 40mg resulted in elevated
anti-Xa levels, especially in those with severe renal dysfunc-
tion [4, 5, 19]. Despite that enoxaparin has shown to accu-
mulate in elderly patients with renal impairment, it is still
widely used and has been studied in medically ill elderly pa-
tients [14, 17, 20].
To date, there is no clear recommendation for the ap-
propriate thromboprophylaxis dosing using enoxaparin
among elderly patients with renal impairment, and
unfractionated heparin is still preferred over LMWH
in those patients [21]. Although heparin is preferred, its
use has associated with a higher risk of bleeding in com-
parison to LMWH [22]. Moreover physicians and nurses
may also prefer LMWH over heparin because of the less
frequent administration. Although enoxaparin is com-
monly prescribed, manufactures of enoxaparin do not
have a unified recommendation for dose adjustment in
renal impairment. Doses of 20 mg or 30 mg subcutane-
ously (SC) once daily are both used, depending on the
country it’s being used in [23–25]. Prescribers usually
adopt institution-specific strategies or opt to prescribe
the dose that is available as a prefilled syringe. In
Lebanon, 20 mg of enoxaparin is available as a prefilled
syringe and hence many providers select this dosing
strategy. A recent retrospective study in Lebanon
showed that enoxaparin 20mg as thromboprophylaxis in
renal impairment resulted in acceptable rates of
thromboembolism and bleeding [26].
To the best of our knowledge, there is no published data
that compares the current recommended VTE prophylac-
tic dosages of enoxaparin 20mg versus 30mg SC in
non-surgical patients with renal impairment, CrCl < 30
ml/min. Therefore, this study aims to evaluate the efficacy
and safety between two different recommended dosing
strategies of enoxaparin, 20mg versus 30mg subcutane-
ously daily for VTE prophylaxis among elderly patients
with a CrCl ≤35ml/min, by comparing anti-Xa levels,
thrombosis and bleeding.
We hypothesize that doses of enoxaparin 20mg versus
30mg subcutaneous in elderly patients with renal im-
pairment may achieve different levels anti-Xa levels thus
possibly affecting the efficacy of thromboprophylaxis in
this setting.
Methods
Trial design
We conducted a prospective, single-blinded, single-center,
randomized clinical trial (ClinicalTrials.gov identifier:
NCT03158792) at the Lebanese American University
Medical Center – Rizk Hospital in Beirut, Lebanon.
Participants, interventions, and study outcomes
Between October 2015 and July 2017, 32 elderly patients
from both acute and critical care settings were enrolled
by all study investigators during medical rounds. The in-
clusion and exclusion criteria of this trial were based on
previous publications [4, 27]. The trial included
non-surgical patients, 70 years of age or older, with renal
impairment, defined by CrCl ≤35 ml/min based on the
Cockcroft-Gault formula, and with an indication for
pharmacological VTE prophylaxis according to the op-
tional hospital risk assessment form or at the discretion
of the physician [28]. To calculate the CrCl, the actual
body was used if actual body weight was less than ideal
body weight. If actual body weight was greater than ideal
body weight (IBW) by more than 20%, adjusted body
weight was used. Adjusted body weight = IBW + 0.4
(actual body weight - IBW). The renal impairment cutoff
was defined as a CrCl ≤35ml/min instead of a CrCl <
30ml/min because of institution specific practices in
dosing anticoagulants to elderly patients with renal im-
pairment. We excluded patients with an indication for a
therapeutic dose of anticoagulant treatment; knee sur-
gery or hip surgery within 10 to 35 days, respectively; re-
cent surgery, hemodialysis, peritoneal dialysis, trauma or
bleeding; history of heparin-induced thrombocytopenia;
known hypersensitivity to enoxaparin; an excessive risk
of bleeding and not eligible for pharmacological throm-
boprophylaxis based on physician assessment or due to
any of the 3 major risk factors including active gastrodu-
odenal ulcer, bleeding within the past three months prior
to hospital admission, or a platelet count of <
50,000 platelets per microliter. Although obesity, defined
as BMI ≥30 kg/m2, was not in the initial set of the exclu-
sion criteria, we excluded patients with obesity in order
not to bias the anti-Xa levels or undertreat patients due
to specific clinical considerations while dosing thrombo-
prophylaxis in extreme body weight [29–31]. We
assigned patients into one of 2 arms: enoxaparin 20 mg
or 30mg SC daily. The primary endpoint was the serum
peak anti-Xa levels, measured on day 3 of thrombopro-
phylaxis, 4 h after the third enoxaparin dose. Secondary
endpoints included trough anti-Xa levels on day 3, mea-
sured before the third enoxaparin dose, the number of
patients achieving a prophylactic target peak anti-Xa
levels within range defined as 0.2–0.4 IU/ml based on
expert opinion, and the occurrence of hemorrhage or
VTE within 30 days assessed from randomization till the
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date of hemorrhage or VTE or the date of discharge,
whichever came first [15, 32]. Hemorrhage was defined
according to the GUSTO criteria [33]. VTE was defined as
objectively detected deep venous thrombosis (DVT) or pul-
monary embolism (PE) by duplex ultrasonography or con-
trast enhanced computed tomography scan, respectively.
Other secondary endpoints included the occurrence of
thrombocytopenia defined as a platelet count of less than
150,000 per microliter and hyperkalemia, defined as a po-
tassium level above 4.7mEq/L as per hospital laboratory
limits. Since both doses are approved for VTE prophylaxis,
no dose adjustments were recommended based on the
anti-Xa levels. Clinical endpoints were not selected as the
primary endpoints due to the limitation in the expected
time to recruit a high number of patients to power the clin-
ical endpoint. This study was approved by the Lebanese
American University Institutional Review Board (LAU
IRB), approval number is LAU.SOP.NC1.25/Jun/2015 and
performed in accordance with the ethical standards as laid
down in the 1964 Declaration of Helsinki and its later
amendments or comparable ethical standards. Informed
consent was obtained from all study subjects or their legal
authorized representative in compliance with ethics com-
mittee regulations. Given that thromboprophylaxis in
non-surgical patients has been proven to benefit patients
with no increase in harm, if patients withdrew consent, they
were not included within the study but continued to receive
thromboprophylaxis at the discretion of their physician.
Sample size, randomization, blinding and data collection
The providers and study investigators were aware of the
treatment allocation, whereas the patients and laboratory
technicians running the blood tests were blinded from the
treatment. Randomization was performed by one of the in-
vestigators who was not involved in data collection. A sam-
ple size of 32 (16 in each arm) was calculated to provide
80% power to detect a difference of 0.10 IU/ml in the mean
anti Xa levels between the two arms, with a standard devi-
ation of 0.10. This is the hypothetical distance between the
midway of the 0.2–0.4 target peak anti Xa range identified
by expert opinion [15, 32]. Block randomization technique
was utilized to allocate subjects into either arm. The Case
Report Form (CRF) was specifically designed for this study,
which collected information about patient demographics,
comorbid illnesses, laboratory results, treatments, adverse
events, and risk of developing VTE according to the
PADUA score, among other information [34].
Statistical methods
Data analysis was carried out using SPSS (version no.24).
Characteristics of the study population were evaluated
using descriptive statistics. Data was expressed as
frequencies and percentages for categorical variables,
means ± SD for numerical variables. Differences in
proportions between the two study arms were evaluated
using the Pearson chi-square or fisher exact test depend-
ing on cell size. Differences in means were tested using
the t-test. Pearson correlation coefficient was used to es-
timate correlations between numerical variables. When
the assumption for normality distribution was violated
bootstrapping was used to correct for potential estima-
tion bias. A two-sided p value < 0.05 was considered sta-
tistically significant.
Results
This study was conducted from October 2015 till July
2017. Forty-seven patients were assessed for eligibility.
Thirty-two patients were randomized to 20 mg and 30
mg enoxaparin groups with 16 in each arm who received
the allocated intervention (Fig. 1).
Table 1 presents patients’ baseline characteristics and
studied parameters per treatment group. The mean
length of follow up was 7 days in both groups. By day
three of thromboprophylaxis, patients in the 20 mg arm
had a statistically significant lower CrCl as compared to
the 30 mg arm (Table 1). The most common VTE
prophylaxis indications according to the PADUA score
were reduced mobility, elderly age followed by acute in-
fection, respiratory failure or heart failure and cancer.
Eight patients in the study required intensive care unit
(ICU) admission, (8/32) patients. In both groups, participants
had a similar past medical history except for more patients
with congestive heart failure (CHF) in the 20mg enoxaparin
group as compared to the 30mg group (p= 0.02).
The assessment of anti-Xa levels was performed to
compare the two treatment strategies and a statistically
significant difference between both the mean peak and
trough anti-Xa levels was noted between the arms.
(Table 2) Seventy-three percent of patients in the enoxa-
parin 30mg arm (8/11) achieved anti-xa levels within the
recommended prophylactic peak range as compared to
38.50% (5/13) in the 20mg arm, p = 0.09. In both arms, no
patient experienced a peak anti-Xa level, above 0.5 IU/ml.
Trough accumulation above 0.1 IU/ml was noted in one
patient in each arm and there was no statistically signifi-
cant difference between the arms (p = 0.99).
Two patients experienced hemorrhage. One patient in
the 20 mg arm, (1/16) experienced hematuria, a minor
bleed, and one patient in the 30mg arm, (1/16) experi-
enced a retroperitoneal bleed and received multiple
transfusions of packed RBCs, a major bleed. No VTE oc-
currences were noted in either arm. Thrombocytopenia
and hyperkalemia occurred in one patient in the 20 mg
arm. Both trough and peak anti-Xa levels were positively
correlated with serum creatinine (SrCr) on day 3 in the
20mg dose arm. Both levels were negatively correlated
with CrCl on day 3 (Figs. 2 and 3).
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Discussion
To our knowledge, this is the first study measuring
anti-Xa levels for enoxaparin 20 mg subcutaneously daily
in elderly patients with renal impairment who are not
on hemodialysis. This study showed that the mean activ-
ity anti-Xa levels, reflecting thromboprophylaxis efficacy,
correlated with the subcutaneous dose of enoxaparin,
with the 20mg dose resulting in a mean anti-Xa activity
level of half that of the 30mg arm. This correlation be-
tween dose and anti-Xa levels is consistent with that re-
ported in other studies [35–39]. In terms of safety, none
of the patients exceeded the recommended anti-Xa
levels, and there was no difference in bleeding events.
Although patients in the 20 mg arm had a significantly
lower CrCl as compared to the 30 mg arm, the former
still had lower peak anti-Xa levels.
To our knowledge, there is no published data com-
paring neither anti-Xa nor clinical endpoints in
elderly patients taking enoxaparin 20 mg compared to
30 mg subcutaneously daily for thromboprophylaxis in
this patient population. In addition, amongst the
studies assessing LMWH for thromboprophylaxis in
patients with renal impairment, only very few studies
have evaluated the incidence of VTE as the primary
endpoint, while other studies evaluated anti-Xa levels
or other pharmacodynamics and pharmacokinetic pa-
rameters [3, 5, 9, 17, 40]. There is limited literature
suggesting that enoxaparin 20 mg subcutaneously is
equally effective in elderly patients when compared to
heparin 5000 units SC BID [41]. Recent literature sup-
porting the use of enoxaparin 20 mg was limited by
the study design that did not include a control group
[26]. Data from the MEDENOX trial showed that 20
mg of enoxaparin was equivalent to placebo in redu-
cing VTE events, but the trial excluded patients with
a SrCr≥1.7 mg/dl or CrCl< 30 ml/min [6]. We ac-
knowledge that the MEDENOX trial excluded patients
with renal impairment, and that our cohort is com-
posed of patients with renal impairment, however as
evidenced by an anti-Xa levels published in subgroup
analysis from the MEDENOX trial, enoxaparin 20 mg
resulted in anti-Xa levels of 0.2 IU/ml [42]. In our
study, even in patients with renal impairment, less
than 50 % achieved anti-Xa levels of 0.2 IU/ml.
Fig. 1 Flow chart. a Due to extreme body weight or due to primary physicians' preference to use other medications such as unfractionated heparin or
tinzaparin. b Participant’s decision: peak anti-xa levels were not available in two patients because in one patient the blood was drawn incorrectly, and
in the second patient participant refused to draw blood for peak level. c Investigator’s decision (Adverse event): participant experienced hematuria
therefore treatment discontinued before the 3rd dose was given, however the trough level was drawn. d Discharged before levels were drawn. e
Three patients discontinued the intervention due to investigator’s decision, one was a man who had low body weight 48 kg and elevated SrCr,
second patient had their third dose discontinued before endoscopic biopsy, third patient was found to have a retroperitoneal bleed after one dose of
enoxapain therefore the treatment was discontinued. f Primary outcome, peak anti-xa levels were not drawn in 3 patients as mentioned above in the
follow up section. As such, only trough levels for these patients were available. g Trough anti-xa level was excluded because sample clotted
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Table 1 Baseline characteristics
Characteristica Enoxaparin 20 mg SC Daily
(n = 16)
Enoxaparin 30 mg SC Daily
(n = 11)
P-value
Age (years) 83.8 ± 6.9 82.1 ± 6.4 0.52
BMI (Kg/m2) 24.1 ± 3.4 28.0 ± 6.3 0.16
Weight (Kg) 63.1 ± 8.3 70.2 ± 12.3 0.11
Padua score 3.5 ± 1.5 3.3 ± 2.1 0.74
Female Gender (%) 68.8 (11/16) 81.8 (9/11) 0.66
Alcohol Use (%) 18.8 (3/16) 36.4 (4/11) 0.39
ICU Admission (%) 37.5 (6/16) 18.2(2/11) 0.41
Chronic Kidney disease (%) 62.5 (10/16) 54.5 (6/11) 0.71
CrCl on day 1 (%)
< 20 56.3 (9/16) 36.4 (4/11) 0.54
20–29 25.0 (4/16) 27.3 (3/11)
30–35 18.8 (3/16) 36.4 (4/11)
CAD (%) 43.8 (7/16) 45.5 (5/11) 0.99
Diabetes (%) 43.8 (7/16) 54.5 (6/11) 0.70
CHF (%) 56.3 (9/16) 9.1 (1/11) 0.02
Cancer (%) 25.0 (4/16) 36.4 (4/11) 0.68
Antiplatelet use on admission
Aspirin (%) 56.3 (9/16) 54.5 (6/11) 0.99
Clopidogrel (%) 12.5 (2/16) 27.3 (1/11) 0.99
Concomitant medications during hospitalization
ARBs (%) 25.0 (4/16) 9.1 (1/11) 0.51
Statin (%) 37.5 (6/16) 27.3 (3/11) 0.69
Aspirin 81 mg–100mg (%) 56.2 (9/16) 63.6 (8/11) 0.99
Clopidogrel 75 mg (%) 18.7 (3/16) 9.1 (1/11) 0.62
Loop diuretics PO (%) 12.5 (2/16) 27.3 (3/11) 0.37
Loop diuretics IV (%) 50.0 (8/16) 36.4 (4/11) 0.70
Aldosterone antagonists (%) 6.2 (1/16) 9.1 (1/11) 0.99
Laboratory trends
Lab day 1 potassium (mEq/L) 4.52 ± 0.93 4.60 ± 0.86 0.83
Lab day 3 potassium (mEq/L) 4.33 ± 0.77 3.95 ± 0.66 0.22
Lab day 1 hemoglobin (g/dL) 10.33 ± 2.08 11.29 ± 1.66 0.29
Lab day 3 hemoglobin (g/dL) 9.58 ± 1.51 10.48 ± 1.50 0.22
Lab day 1 Platelets, (per microliter) 270,692 ± 148,970 302,250 ± 133,511 0.63
Lab day 3 Platelets (per microliter) 206,333 ± 63,532 263,428 ± 86,061 0.12
Lab day 1 SCr (mg/dL) 2.62 ± 1.25 2.15 ± 1.13 0.34
Lab day 3 SCr (mg/dL) 2.82 ± 1.22 2.31 ± 1.76 0.37
Mean SCr (mg/dL) 2.72 ± 1.15 2.28 ± 1.46 0.39
Lab day 1 CrCl (mg/dL) 19.71 ± 8.76 24.57 ± 8.13 0.15
Lab Day 3 CrCl (mL/min) 17.52 ± 6.75 28.22 ± 14.52 0.02
Mean CrCl (mg/dL) 18.55 ± 7.33 25.97 ± 10.49 0.04
Abbreviations: CrCl creatinine clearance, CAD coronary artery disease, CHF congestive heart failure, ARBs angiotensin receptor blockers, SCr serum creatinine
aData are mean ± SD values unless otherwise indicated
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Peak anti-Xa levels were used as the primary endpoint
since they have been shown to correlate more strongly
with safety and efficacy than trough levels [43]. There is
no clear consensus on peak anti-Xa levels for prophylac-
tic doses of enoxaparin, however, many references rec-
ommend a level of < 0.5 IU anti-Xa /ml since anti-Xa
target levels for VTE treatment dose range between 0.5–
1.0 units/ml for twice daily regimens [12, 19, 44, 45]. Al-
though anti-Xa levels as a surrogate marker has not been
verified as an indicator of clinical antithrombotic efficacy
in non-surgical patients, monitoring anti-Xa levels is rec-
ommended to guide dose optimization in high-risk pa-
tients [42, 46]. Furthermore, Levine et al. showed a
statistically significant relationship between anti-Xa level
and thrombosis among orthopedic patients receiving
thromboprophylaxis [4, 47].
In our study, enoxaparin 20 mg yielded anti-Xa levels
lower than those previously reported despite the fact
that our peak levels were sampled on the third dose
which could have allowed for accumulation. Sanderink
et al. described a 29% increase in anti-Xa levels after 4
days of thromboprophylaxis in patients with a CrCl < 30
ml/min, which was explained by a prolonged half-life
and decrease in renal elimination in comparison to
healthier adults [5]. Although there is insufficient data to
make assessments between anti-Xa levels and prophylac-
tic efficacy, the lower than recommended mean anti-Xa
levels observed in this trial should be taken into consid-
eration pending the availability of clinical thrombotic
endpoint data [9].
On day 3 of thromboprophylaxis, we found a positive
and an inverse correlation between anti-Xa levels in the 20
mg arm with SrCr and CrCl, respectively. Such correlation
may be due to the lower CrCl (mean of 17.3ml/min) in the
20mg arm, and this has been previously described in litera-
ture in patients with a CrCl< 30ml/min [4].
Much of the published literature focuses on risk of
bleeding in patients with renal dysfunction on thrombo-
prophylaxis. In patients with advanced renal impairment
(CrCl < 30 ml/min) receiving enoxaparin for VTE
prophylaxis, the rates of bleeding reported in literature
range between 0 and 6% [4, 9, 40]. Moreover, in patients
with severe bleeding complications, the anti-Xa levels
were either undetectable or the same as other patients
in the study [4]. The rates of bleeding observed in our
cohort were similar 6.25% (1/16) patients in each arm.
Moreover, anti-xa levels do not appear to be related to
bleeding risk in patients with significant renal impairment.
Table 2 Primary and Secondary outcomes: Peak and trough anti-xa levels achieved with each enoxaparin dose
Outcomesa Enoxaparin 20mg
SC daily (n = 16)
Enoxaparin 30mg
SC daily (n = 11)
P-value
Peak anti-xa level (IU/mL) 0.14 ± 0.09
(0.08–0.19)
0.26 ± 0.11
(0.18–0.34)
0.004
Trough anti-xa level (IU/mL) 0.03 ± 0.04
(0.01–0.05)
0.06 ± 0.03
(0.04–0.08)
0.044
Abbreviations: SC Subcutaneous
a Data are mean ± SD (95%CI) values unless otherwise indicated
Fig. 2 Correlation of Trough anti-Xa levels with creatinine clearance (CrCl) at day 3. For 20mg group r =− 0.659 p= 0.005, for 30mg r=− 0.173 p= 0.632
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This trial represents the first study to characterize
anti-Xa levels in patients on enoxaparin 20mg versus 30
mg in elderly patients with renal impairment. This pa-
tient population is at an increased risk of bleeding and
dose optimization or the selection of safer alternatives in
renal impairment is essential to ensure a favorable risk/
benefit ratio. We acknowledge the limitations to our
study namely the small sample size, short duration of
follow up and the use of a CrCl cut off of ≤35ml/min
instead of < 30ml/min. This less stringent cut off was
adopted based on the concern that CrCl may over pre-
dict the glomerular filtration rate [48]. Although dosing
references recommend the CrCl as calculated by the
Cockcroft-Gault formula for medication dose adjust-
ments, clinical judgment is recommended based on the
physiologic changes in elderly patients [49]. The lower
lean body mass, reduced intake of proteins and malnu-
trition all affect the production and secretion of creatin-
ine and therefore the CrCl. Moreover, in patients with
acute kidney injury, the rise in serum creatinine usually
lags behind the kidney injury, therefore not immediately
reflecting the extent of the kidney injury [50]. Further-
more, two patients recruited into the study had received
unfractionated heparin as thromboprophylaxis and were
then switched to enoxaparin after 12 h. One patient in
the 30mg arm had received 1 dose of heparin 5000 SC
BID, whereas one patient in the 20 mg arm had received
34 doses of heparin 5000 units SC BID. After excluding
these patients from the analysis, the anti-Xa levels were
still consistent with the results, enoxaparin 20mg peak
anti-Xa levels 0.13 ± 0.10 vs enoxaparin 30mg 0.27 ±
0.11, p = 0.004 and enoxaparin 20mg trough anti-xa
levels were 0.03 ± 0.03 vs enoxaparin 30mg 0.06 ± 0.03,
p = 0.038. It is important to note that although CHF was
more common in the 20 mg arm, which may have led to
decreased subcutaneous absorption, a sensitivity analysis
excluding all patients with CHF from both arms showed
consistent findings with the overall study results. The
enoxaparin 20mg peak anti-Xa levels were 0.11 ± 0.10 vs
enoxaparin 30 mg 0.26 ± 0.11, p = 0.010 and enoxaparin
20mg trough anti-xa levels were 0.02 ± 0.02 vs enoxa-
parin 30mg 0.06 ± 0.03, p = 0.012.
Conclusion
In conclusion, this study showed that thromboprophylaxis
with enoxaparin 30mg provides higher control of anti-Xa
activity in non-surgical elderly patients with renal impair-
ment in comparison to enoxaparin 20mg. In light of min-
imal available data evaluating the efficacy of enoxaparin
20mg for thromboprophylaxis in renal impairment, and
in context of the observed anti-xa levels, it may be safer
for providers to use enoxaparin 30mg SC.
Abbreviations
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